University of Pennsylvania

ScholarlyCommons
Dental Theses

Penn Dental Medicine

Spring 6-19-2017

FOXO1 Deletion Reverses the Effect of Diabetic-Induced Impaired
Fracture Healing
Mohammed A. Alharbi
King Abdulaziz University, Saudi Arabia, alharbi.mohammed@hotmail.com

Follow this and additional works at: https://repository.upenn.edu/dental_theses
Part of the Dentistry Commons

Recommended Citation
Alharbi, Mohammed A., "FOXO1 Deletion Reverses the Effect of Diabetic-Induced Impaired Fracture
Healing" (2017). Dental Theses. 23.
https://repository.upenn.edu/dental_theses/23

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/dental_theses/23
For more information, please contact repository@pobox.upenn.edu.

FOXO1 Deletion Reverses the Effect of Diabetic-Induced Impaired Fracture
Healing
Abstract
Objectives:
Abstract
Diabetes impairs fracture healing. Our laboratory previously suggested that a dominant mechanism was
the premature loss of cartilage during endochondral bone formation. Based on these results we tested
the hypothesis that chondrocytes regulate osteoclast formation in diabetes-impaired fracture healing and
that it is controlled by the transcription factor FOXO1.
Methods:
Closed fracture of the femur was induced in mice with lineage-specific FOXO1 deletion in chondrocytes
Col2α1Cre+/FOXO1L/L and Col2α1Cre-/ FOXO1L/L as control mice that had FOXO1 gene present. Mice
were rendered diabetic by multiple streptozotocin injections. The normoglycemic group received vehicle
alone. Specimens were collected at 10 days (cartilage formed), 16 days (transition from cartilage to bone
formation) and 22 days (primary bone formed). The cartilage area was measured using safranin-O/fast
green staining. Osteoclasts were counted as TRAP positive cells. The expression of cathepsin K and
RANKL were determined by quantitative immunostaining with specific antibodies compared to control
IgG. Micro CT was used to measure the callus volume and the mineralized bone. Statistical analysis was
done using a one-way ANOVA test. Results with p
iv
Results:
All the groups showed similar cartilage areas at day 10. At day16 the diabetic group had 77% less
cartilage area than the normal (P
Conclusion:
Our data indicates that FOXO1 drives RANKL expression in chondrocytes and resorption of cartilage.
FOXO1 deletion reverses diabetes-enhanced osteoclast formation and prevents the premature loss of
cartilage, which results in a better bone healing.
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Abstract
Objectives:
Diabetes impairs fracture healing. Our laboratory previously suggested that a
dominant mechanism was the premature loss of cartilage during endochondral
bone formation. Based on these results we tested the hypothesis that
chondrocytes regulate osteoclast formation in diabetes-impaired fracture
healing and that it is controlled by the transcription factor FOXO1.

Methods:
Closed fracture of the femur was induced in mice with lineage-specific FOXO1
deletion in chondrocytes Col2α1Cre+/FOXO1L/L and Col2α1Cre-/ FOXO1L/L as
control mice that had FOXO1 gene present. Mice were rendered diabetic by
multiple streptozotocin injections. The normoglycemic group received vehicle
alone. Specimens were collected at 10 days (cartilage formed), 16 days
(transition from cartilage to bone formation) and 22 days (primary bone
formed). The cartilage area was measured using safranin-O/fast green
staining. Osteoclasts were counted as TRAP positive cells. The expression of
cathepsin K and RANKL were determined by quantitative immunostaining with
specific antibodies compared to control IgG. Micro CT was used to measure
the callus volume and the mineralized bone. Statistical analysis was done
using a one-way ANOVA test. Results with p<0.05 were considered
significant.
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Results:
All the groups showed similar cartilage areas at day 10. At day16 the diabetic
group had 77% less cartilage area than the normal (P <0.05). The accelerated
cartilage loss in the diabetic group was completely reversed when FOXO1in
chondrocytes was deleted (P<0.05). Diabetic mice had 4.4 times more
cathepsin K positive cells in comparison to normal littermates. This change
could be accounted for by changes in RANKL expression, which was 2-fold
greater in the diabetic mice, compared to the normal mice (P <0.05). However,
when FOXO1 in chondrocytes was deleted in the diabetic animals, osteoclasts
numbers were reduced to normal levels (P <0.05). Bone volume in the diabetic
group was 29% and 34% less than the normoglycemic animals on day 16 and
day 22 respectively (P <0.05). However, the effect of diabetes was rescued to
normal levels upon FOXO1 deletion in chondrocytes (P <0.05).

Conclusion:
Our data indicates that FOXO1 drives RANKL expression in chondrocytes and
resorption of cartilage. FOXO1 deletion reverses diabetes-enhanced
osteoclast formation and prevents the premature loss of cartilage, which
results in a better bone healing.
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Introduction
Normal Fracture Healing:
Long bone fracture healing is a dynamic process that involves complex
and coordinated activities of stem cells, inflammatory cells, chondrocytes,
osteoblasts, osteoclasts, and other cell types. (L. Gerstenfeld, Cullininane,
Barnes, Graves, & Einhorn, 2003). This occurs via two dynamic interactive
responses. The first is the intramembranous bone formation, which is
characterized by direct bone formation without using cartilage as a template.
The periosteum is the primary source of cells involved in this phase. Those
cells are predominantly osteoprogenitor and undifferentiated mesenchymal
cells (Einhorn, 1998). The second is the endochondral bone formation.
Endochondral bone formation is a process that involves recruitment,
proliferation, and differentiation of undifferentiated mesenchymal stem cells
into cartilage producing chondrocytes (Einhorn, 1998). Cartilage is eventually
calcified, resorbed and replaced by bone.
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Figure1: Long bone fracture healing stages. The callus primarily consists of
hematoma and immune cells at the inflammatory phase, un-calcified
cartilaginous soft callus at the second phase, calcified intermixed hard callus,
and finally the remodeling phase at which the callus will remodel to restore the
original morphology.
The fracture healing process can be divided into three interconnected
phases, initial inflammatory phase, regenerative phase, and finally a
remodeling phase. Like most other injuries, at the initial phase an inflammatory
process will start and a hematoma will form from blood cells extravasating the
damaged blood vessels. Those cells will produce cytokines, which will
increase the blood capillary permeability (Einhorn, 1998). In addition to the
blood cells, this phase involves the infiltration of different inflammatory cells
including macrophages. Macrophages release various cytokines and
chemokines that help to recruit other inflammatory cells, enhance the
angiogenesis, and finally promote matrix formation. (Einhorn, Majeska, Rush,
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Levine, & Horowitz, 1995; L. C. Gerstenfeld et al., 2003). Furthermore, at this
early stage platelets play a primary role in the initial healing phase. They
aggregate and are considered a major source of platelet-derived growth factor
(PDGF) and transforming growth factor-β (TGF-β) that are important for both
the recruitment and the differentiation of mesenchymal stem cells (Bolander,
1992). Bone-marrow-derived MSCs differentiate to either cartilage forming
chondrocytes or bone forming osteoblasts; both of which are critical for
endochondral ossification of fractured calluses. MSCs mediate and enhance
angiogenesis in addition to their role in reducing inflammation and apoptosis.
(Caplan & Dennis, 2006; Cho, Gerstenfeld, & Einhorn, 2002; Shea, Edgar,
Einhorn, & Gerstenfeld, 2003) .
The initial stability of the fractured segments is provided by the cartilage.
Chondrocytes will populate the fracture area and will deposit soft matrix that
constitutes the soft callus. Those chondrocytes express type II collagen in
addition to aggrecan which is a significant feature of mature chondrocytes
(Sandberg, Aro, Multimaki, Aho, & Vuorio, 1989). Chondrocytes will then
release growth factors and cytokines that induce osteogenesis (L. C.
Gerstenfeld et al., 2002). Chondrocytes will then differentiate into a
hypertrophic phase characterized by expressing type X collagen (Barnes,
Kostenuik, Gerstenfeld, & Einhorn, 1999). Cartilage matrix undergoes
degradation by collagenases and proteases, predominantly MMP and
disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin-
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type 1 motifs (ADAMTs). Cartilage degradation and breakdown facilitate the
formation and the invasion of new blood vessels via VEGF and angiopoietin
dependent pathways that facilitate the recruitment of osteoclasts and
osteoblasts (Peng et al., 2005). RANKL also induces the production of
chemokines, suggesting an amplification loop during recruitment of precursors
and differentiation of osteoclasts [12]. Little attention was given to
chondrocytes as a source of RANKL in the literature. Martínez-Calatrava,
Maria J., et al. looked at the expression of RANKL in chronic arthritis rabbit
model. They have found that chondrocytes had very high RANKL expression
in the osteoarthritis group and the expression of RANKL was proportional to
the articular bone loss observed in that group.(Martinez-Calatrava et al., 2012)
The apoptosis phase of the hypertrophic chondrocytes is a critical
phase during fracture repair (F. Y. Lee, Choi, Behrens, DeFouw, & Einhorn,
1998; Li, White, Connolly, & Marsh, 2002). There is a direct relationship
between the vasculature and the rate of apoptosis and resorption of cartilage.
This process is mediated in part by the tumor necrosis factor alpha (TNF-α). It
has been reported that TNF-α enhances the apoptosis of chondrocytes and
upregulates the levels of pro-resorptive cytokines that regulate the remodeling
phase by osteoclasts (L. C. Gerstenfeld et al., 2003).
The main source of the bone forming cells (osteoblasts) that repair the
fractured bone during endochondral ossification remains controversial. There
are two different theories; the first one is that the fully differentiated
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hypertrophic chondrocytes undergo programmed apoptosis and the progenitor
cells from the blood vessels penetrate the cartilage callus which is undergoing
degradation to replace the cartilage with bone. The second hypothesis is that
some of the fully differentiated hypertrophic chondrocytes do not undergo
apoptosis; however, they transdifferentiate into bone forming osteoblasts.
Recent investigations using contemporary genetic lineage-specific tracing
methods concluded the both pathways work parallel to each other. However,
chondrocyte transdifferentiation into osteoblasts was the predominant pathway
during the endochondral process (Bahney et al., 2014; X. Zhou et al., 2014).
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Figure 2: A new endochondral ossification model for fracture healing.
Stem cells from the periosteum and the endosteum will differentiate to form
bone and cartilage forming cells. The early soft callus will be formed by the
osteochondral progenitors differentiating into chondrocytes. Those
chondrocytes undergo hypertrophic differentiation and will secrete potent
angiogenic factors that result in the vascular invasion at the transitional zone
which will facilitate the mineralization of the cartilage. Some hypertrophic
chondrocytes will undergo apoptosis to create marrow space within the
trabecular bone. Other hypertrophic chondrocytes regain some stem cell-like
properties by expressing the pluripotent transcription factors OCT4, SOX2 and
NANOG. These large cells re-enter the cell cycle, divide and then transform
into osteoblasts. (Picture copied from Bahney et al., 2014)
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Osteoclasts are the cells that normally line bones and are responsible
for its resorption. Osteoclasts are large multinucleated cells that range
between 150-200 µm in diameter. During fracture healing, osteoclasts resorb
the cartilage within the healing callus. Receptor activator of NFκB Ligand
(RANKL), Macrophage colony stimulating factor (MCSF), and Osteoprotegerin
(OPG) are considered the key regulators of osteoclasts activation (Kon et al.,
2001). Cathepsin K is a member of peptidase C1 protein family which is
expressed predominantly by osteoclasts and it is secreted into the resorptive
pit. Cathepsin K is a protease that is capable of catabolizing type I collagen,
elastin, and gelatin that enables the osteoclasts to resorb calcified tissue such
as bone and cartilage. Once the osteoclast reaches the resorption site,
cathepsin K is secreted into the resorptive pit from the ruffled border. It
transmigrates by the intercellular vesicles with reactive oxygen species formed
by TRAP to breakdown the ECM. A cathepsin K knock out mouse model
showed an osteopetrotic phenotype. Osteopetrosis is defined as "stone bone”
and it is also known as marble bone disease. It is a genetic disorder that
affects the bone making it extremely dense and harder. On the other hand,
Osteoporosis is another more common condition in which the bone becomes
very brittle and has a very low density. In osteopetrosis, the number of
osteoclasts may be reduced, normal, or increased. Most importantly,
osteoclast dysfunction mediates the pathogenesis of this disease.(Aker et al.,
2012)
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While the cartilage is undergoing resorption, osteoblasts secrete bone matrix
which undergoes calcification to form the woven bone which represents the
bony callus (Dimitriou, Tsiridis, & Giannoudis, 2005). Bone morphogenic
proteins are upregulated during this phase and they regulate osteoblasts
recruitment, differentiation, and maturation (Cho et al., 2002). At the final stage
of the fracture healing, this bony callus will remodel to the primary structure
and morphology of the unfractured bone. Another set of cytokines are elevated
during the remodeling phase including, but not limited to, TNF-α, IL-1 and IL-6
(Kon et al., 2001).
Diabetes Mellitus:
Diabetes mellitus (DM) is a serious concern in the United States and
worldwide as the incidence of this chronic disease has been rapidly increasing
in the past 20 years. Today it is estimated that 415 million people worldwide
are diagnosed with diabetes (IDF DIABETES ATLAS 6th edition 2015). DM is
a disease characterized by high blood glucose level (hyperglycemia) due to
insulin deficiency or due to the inability of the body cells to respond to the
insulin secretion. There are two major types of diabetes mellitus, type 1(TIDM)
and type 2 (T2DM).
Type 1 is characterized by the destruction of Beta cells in the pancreas. The
cause of type 1 diabetes is not known, although a number of possible
hypotheses have been proposed. These predominant hypotheses are genetic
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susceptibility, a diabetogenic trigger, and the exposure to an antigen. Type 1
diabetes usually occurs following autoimmune response initiated by pancreatic
inflammation and predominant infiltration of macrophages into the pancreatic
islets (O'Reilly et al., 1991). Macrophages will stimulate the cytotoxic Tlymphocytes which will secrete antibodies against beta cells (Jun, Santamaria,
Lim, Zhang, & Yoon, 1999). They will also stimulate the production of a
number of proinflammatory cytokines such as inertleukin-1β (IL-1β), interferonγ (IFN-γ), TNF-α. The combination of inflammatory cells infiltration and the
production of the proinflammatory cytokines will lead to further destruction of
beta cells promoting their apoptosis (Christen et al., 2001; Green, Eynon, &
Flavell, 1998; Suarez-Pinzon et al., 1999; von Herrath & Oldstone, 1997).
Type 2 diabetes is more prevalent and it is associated with very high
insulin resistance. It has been reported that the incidence of type 2 diabetes is
directly related to increased visceral adipogenesis (Colditz et al., 1990; Kahn &
Flier, 2000; Mokdad et al., 2003). Adipocytes can release molecules that alter
the insulin response by the body, which will enhance the insulin resistance.
(Greenberg & Obin, 2006). During the early onsets of type 2 diabetes, the
pancreatic beta cells will overproduce insulin to compete with the body’s
resistance. This hyperinsulinemia usually leads to an increase in pancreatic
cell mass (Dickson & Rhodes, 2004). Thus, these individuals do not develop
diabetes. However, in many cases, the beta cell mass will undergo apoptosis.
This results in the inability of the body to compensate for the insulin resistant
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status and subsequently will result in sustained hyperglycemia leading to a
diagnosis of type 2 diabetes. Thus, type 2 diabetes is characterized by both
insulin resistance coupled with insufficient production of insulin to overcome
the insulin resistance (Donath, Storling, Maedler, & Mandrup-Poulsen, 2003).
Furthermore, a less common form of diabetes is gestational diabetes.
Some pregnant women may undergo temporary changes in their metabolism
including lowering their insulin sensitivity. The reduced insulin sensitivity will
result in glucose intolerance. This condition is called gestational diabetes
mellitus and it is defined as glucose intolerance first recognized in pregnancy
(Dornhorst & Beard, 1993). The epidemiological studies of gestational
diabetes show that it is widely variable and ethnicity-dependent. A family
history of diabetes, as well as the maternal weight were all considered as
predisposing factors to gestational diabetes (H. King, 1998; Xiong, Saunders,
Wang, & Demianczuk, 2001).
Diabetic complications:
Mechanisms of Diabetic Complications
Diabetes is associated with a number of reported factors that can lead
to diabetic complications such as enhanced oxidative stresses, enhanced
formation of advanced glycation end products (AGEs), increased the levels of
protein kinase C activation (PKC), and shunting through the polyol pathway
(Figure 3).
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Diabetes is associated with downregulation of anti-oxidants as well as
upregulation of superoxides (Giugliano, Ceriello, & Paolisso, 1996; Hunt &
Wolff, 1991; Wolff & Dean, 1987). One of the negative impacts of
hyperglycemia can happen through overloading the mitochondria. Once the
mitochondria becomes overloaded its electron transport chains becomes
dysregulated. This dysregulation leads to the release of electrons which react
with oxygen and results in overproduction of superoxides, which will increase
the oxidative stress inside the cell (Brownlee, 2005). It has been reported that
the overexpression of reactive oxygen species (ROS) can harm cell
membranes and can denature proteins. (Baynes & Thorpe, 1999).
Furthermore, ROS can enhance the immune response through the activation
and stimulation of cytokine secretions (Millar, Phan, & Tibbles, 2007; Mitra &
Abraham, 2006). In addition, ROS was reported to be associated with
enhancing inflammation by activating nuclear translocation of nuclear factor of
kappa light chain gene enhancer in B-cells NF-κB (Gloire, Legrand-Poels, &
Piette, 2006).
Many reports showed that aging, obesity, and hyperglycemia are
associated with enhanced formation of AGE’s (He, Koschinsky, Buenting, &
Vlassara, 2001; He et al., 2000; G. L. King & Brownlee, 1996; Stitt & Curtis,
2005; Vlassara & Bucala, 1996; Wada & Yagihashi, 2005; Yan, Ramasamy,
Naka, & Schmidt, 2003). AGE’s can cause cross-linking of the cell membrane
as well as denaturing proteins, which will result in altering many cellular and
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molecular activities. (G. L. King & Brownlee, 1996; Stitt, He, & Vlassara, 1999;
Vlassara & Bucala, 1996). AGE’s can also enhance the recruitment of different
inflammatory cells including mononuclear phagocytes. Furthermore, AGE’s
can also increase osteoclastic activities and facilitate bone resorption in
cultured mouse bone cells (Miyata et al., 1997). Finally, it has been reported
that AGE’s- RAGE combination blocked MSC differentiation to chondrocytes
or osteoblasts and it enhanced the programed cell death (Kume et al., 2005).
Hyperglycemia is a sustained state of excessive glucose levels inside
the tissues. The excess glucose leads to the activation of the polyol pathway
and subsequently elevates the levels of both sorbitol and fructose (Gabbay,
1973). Shunting through the polyol pathway increases the production of
AGE’s, ROS, and nitric oxide (NO) (Cameron & Cotter, 1992; Hamada, Araki,
Horiuchi, & Hotta, 1996; G. L. King & Brownlee, 1996; Stevens et al., 1994).
High glucose is associated with activating PKC, nuclear translocation of (NFκB), and dephosphorylating of the inhibitor of NF-κB kinase (IKK). Blocking
aldose reductase in diabetic conditions blocks these effects (Ramana,
Bhatnagar, & Srivastava, 2004a, 2004b; Ramana, Friedrich, Srivastava,
Bhatnagar, & Srivastava, 2004; Ramana et al., 2005; Srivastava, Ramana, &
Bhatnagar, 2005).
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Figure 3: Mechanisms of diabetic complications. Hyperglycemia caused by
diabetes leads to an increased oxidative stress, activation of the polyol
pathway, the formation of AGE’s, and increased PKC activity. These factors
increase proinflammatory cytokine expression, enhance PMN and monocyte
recruitment, and impair bacterial killing. These alterations may contribute to
complications seen in diabetes.
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Diabetes and bone fractures:
It has been reported that there is an increased risk of fractures of the
long bones in patients with TIDM (odds ratio = 2.2) and T2DM (odds ratio =
2.8) (Hernandez, Do, Critchlow, Dent, & Jick, 2012). Furthermore, in T1DM
the relative risk of hip fracture was 6.9 after adjusting for age, body mass
index and smoking (Forsen, Meyer, Midthjell, & Edna, 1999; Vestergaard,
Rejnmark, & Mosekilde, 2005). One of the possible mechanisms is through
decreased bone mineral density and osteopenia. (Hamada et al., 2007; Jehle,
Jehle, Mohan, & Bohm, 1998; Kemink, Hermus, Swinkels, Lutterman, &
Smals, 2000; Piepkorn et al., 1997; Tuominen, Impivaara, Puukka, &
Ronnemaa, 1999). Kemink et al. reported that 67% of diabetic men and 57%
of diabetic women had osteopenia of either the femoral neck and/or the
lumbar spine. They have also reported that the diabetic patients had a lower
level of plasma insulin-like growth factor (IGF) in comparison to the normal
control. Furthermore, they have indicated that within the diabetic group of
patients, those who had femoral neck osteopenia had significantly lower
plasma IGF-1 levels compared to those without osteopenia (Kemink et al.,
2000). The mechanisms of osteopenia caused by diabetes have been
thoroughly investigated. In one investigation, they found that individual with
type 1 diabetes had lower BMD and they found a drastic reduction in the
serum levels of osteocalcin. Osteocalcin is a noncollagenous hormone
secreted primarily by osteoblasts and odontoblasts in a vitamin K-dependent
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process. Osteocalcin plays a major role in the mineralization of hard tissues in
addition to its role in the homeostasis of calcium. Osteocalcin also behaves as
a hormone that stimulates pancreatic cells to release more insulin into the
system.

Figure 4: Mechanisms of how diabetes reduces bone formation. The
hyperglycemia caused by diabetes will enhance and prolong the inflammation
status of the body which will enhance the formation of AGEs, ROS and
reduction in insulin signaling. Those events will affect osteoblasts and will
reduce bone formation via dysregulating BMPs, Runx2, or Fra1. Copied from
(Jiao, Xiao, & Graves, 2015)
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Another group of investigators suggested that the osteopenia caused
by diabetes is not only due to decreased bone formation but, also as a result
of increased bone resorption associated with IGF deficiency. They have
measured urinary deoxy pyridinium crosslinks, which is a marker of bone
resorption, in diabetic patients and they have reported that it was significantly
upregulated compared to matched controls (Bjorgaas, Haug, & Johnsen,
1999). Since type 1 diabetics are typically deficient in insulin, it has been
proposed that the hypoinsulinemic status rather than the hyperglycemic effects
of diabetes is the causative factor for bone dysregulation (Thrailkill, Lumpkin,
Bunn, Kemp, & Fowlkes, 2005). However, a study on euglycemic mice, mice
with tissue-specific insulin receptor deficiency, showed that those mice had
normal bone mass. Besides, those mice had normal mRNA levels of both
osteocalcin and runt-related transcription factor 2 (Runx2). All those findings
indicate that osteopenia caused by diabetes is due to hyperglycemia rather
than hypoinsulinemia (Irwin, Lin, Motyl, & McCabe, 2006).
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Figure 5: Mechanisms of how diabetes increases osteoclastogenesis.
Hyperglycemia caused by diabetes enhances inflammation and the production
of AGEs, ROS, and will decrease insulin signaling. This will lead to alteration
in the RANKL/OPG ratio which will increase osteoclast formation (Copied from
(Jiao et al., 2015).
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Streptozotocin-induced animal model:
Streptozotocin (STZ) induced diabetes is a commonly used animal
model because it is straightforward and reproducible (Lenzen, 2008). STZ (2deoxy-2-(3-methyl-3- nitrosourea)-1-D-glucopyranose) is a broad-spectrum
antibiotic synthesized by Streptomyces achromogenes. It has a structure that
is similar to glucose and N-acetyl glucosamine (GlcNAc) which facilitate its
transportation to the pancreatic β cells. This transport is exclusive by glucose
transport protein GLUT2 but not by other transporters (figure 6). It has been
reported that β cells have very high levels of GLUT2 which would explain the
high toxicity of STZ on β cells (Schnedl, Ferber, Johnson, & Newgard, 1994;
Z. Wang & Gleichmann, 1998). Once STZ is transported into the cells, it
induces cell death through different suggested pathways. First, the formation
of carbonium ions (CH3+) will result in activating poly ADP-ribose synthetase
resulting in DNA methylation. The second pathway works via increased
production of hydrogen peroxide and other free radicals that will promote the
cell’s death. Finally, STZ might increase nitric oxide levels within the cells
which will accelerate the cell death process. (Szkudelski, 2001; Tesch & Allen,
2007)
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Figure 6: Chemical structures of (A) glucose, (B) N-acetyl glucosamine
and (C) streptozotocin
Several studies using STZ-induced diabetes showed the negative
impact of the disease on bone. There was a significant reduction in bone
mineral density as well as bone mineral content in STZ induced diabetic
animals. Moreover, the levels of osteocalcin in the serum were also
significantly reduced compared to non-diabetic animals. (Botolin et al., 2005;
Hou, Zernicke, & Barnard, 1991). Also, STZ induced diabetic animals had
around 20-30% decrease in the biomechanical strength of both femurs and
tibias (Hou et al., 1991; Reddy, Stehno-Bittel, Hamade, & Enwemeka, 2001).
As previously mentioned, diabetes is associated with enhanced AGE’s
production, and the role of upregulated AGE’s in diabetic complications is
already well established. Santana and colleagues showed the association
between higher levels of RAGE in diabetic animals and the reduction in bone
forming capability of STZ-induced diabetic mice compared to the matched
controls. Besides, there was a significant reduction in the bone forming ability
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upon treating normal animals with AGE’s to levels matching the diabetic
animals (Santana et al., 2003). Alikhani et al. showed both in vitro and in vivo
the upregulation in osteoblast apoptosis associated with AGE’s treatment
which might explain the significant reduction in the bone forming capacity
associated with AGE’s upregulation. In addition to increasing osteoblasts
apoptosis, it has been reported that AGE’s were associated with increased
osteoclastic activities through upregulating the production of the
proinflammatory cytokine IL-6 (Miyata et al., 1997)
Our lab has previously shown that diabetes causes premature cartilage
resorption. Although the mechanism of how diabetes negatively affects the
fracture healing is unknown, our lab has proposed a dominant mechanism
which is the premature cartilage resorption via upregulation in osteoclastic
activates. Our lab has shown that diabetes resulted in smaller cartilage areas
at the transitional time. (Kayal et al., 2007). During fracture healing, there was
double the number of osteoclasts in the calluses of diabetic animals compared
comparison to normal animals. The striking change in osteoclast numbers was
associated with significantly higher mRNA levels of RANKL in the diabetic
animals (Kayal et al., 2007). Tsentidis et al. suggested a reduction in IGF1 as
a mechanism of diabetes enhanced total s-RANKL (Tsentidis et al., 2016). Our
lab has also shown that the diabetic-induced upregulated osteoclastogenesis
was TNF-α dependent, and when the diabetic mice were treated with a TNF-α
inhibitor, they exhibited normal osteoclastic activities. TNF-α upregulation in
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diabetes may reduce the capacity to downregulate other inflammatory and
apoptotic genes which have been linked to the reduction in bone coupling in
diabetic animals. Prolonged overexpression of TNF-α leads to upregulation in
nuclear factor-kappa-B activity and will diminish the levels of fra-1 and runx2
which are potent stimulators for osteoblast migration, proliferation, and
differentiation. Furthermore, TNF-α overexpression has been linked to the
reduction in osteoblast numbers through increasing programed cell death via
activating caspase 3 and altering Bax/Bcl-2 ratio (Coe, Irwin, Lippner, &
McCabe, 2011). In another investigation, our lab has shown that diabetes
causes upregulation of inflammatory cytokines and chemokines expressed by
chondrocytes. The overexpression of those cytokines and chemokines might
play an important role in the diabetic-induced impaired fracture healing.
Furthermore, those cytokines and chemokines were mediated in part by the
transcription factor forkhead box O1 (FOXO1) (Alblowi et al., 2013).
FOXO1:
Forkhead box (FOX) transcription factor was first found in Drosophila. It
was then cloned and characterized in humans by homology. FOXO is a family
of transcription factors involved in many cellular and molecular events. FOXO
transcription factors are a member of a big family of forkhead proteins
characterized by the presence of a winged-helix DNA binding domain called
Forkhead box (Almeida, 2011). They are currently the largest family of
transcription factors in humans, and they have been grouped according to
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their structural characteristics into four subclasses; FOXO1 (or FKHR),
FOXO3 (also known as FKHRL1), FOXO4 ( which is also called AFX) and
FOXO6 (Greer & Brunet, 2005). All the members of this subfamily are highly
expressed in bone and cartilage forming cells, except FOXO6, which is
expressed exclusively in the brain (Jacobs et al., 2003). It has been reported
that these family members are key regulators in processing various stimuli
such as inflammation, hormonal changes, increased oxidative stresses and
free radicals into different physiological and pathological events. Furthermore,
FOXO1 activities regulate several genes that control glycogenesis and
gluconeogenesis.
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Figure 7: Mechanisms of FOXO1 activation. FOXO1 translocate into the
nucleus in the absence of insulin which will lead to activation of all the FOXO1
dependent cascades. (picture copied from Current Biology)
Insulin plays a major role in regulating FOXO1 activities since the
deactivation of this transcription factor is mediated by the insulin/PI3K/AKT
signaling pathway. Several pathways are activated through insulin receptor
signaling. One of those pathways is Ras which will activate MAP kinase.
Furthermore, insulin also induces the phosphorylation of insulin receptor
substrate 1 (IRS-1) and IRS-2 and the activation of phosphatidylinositide-3kinase (PI3K), which will subsequently activate AKT. Insulin resistance can
lead to the reduction in the phosphorylation of IRS-1/IRS-2. The reduction in
IRS-1 and IRS-2 activities will reduce PI3K activities and will increases MAP
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kinase activation. AKT signaling regulates the activation of FOXO1 and is
critical in controlling homeostasis. FOXO1 is deactivated by phosphorylation
via AKT and SGK1 at three different sites. The phosphorylation process of
FOXO1 reduces the DNA binding activities of this transcription factor and will
facilitate its transport outside the nucleus to the cytoplasm, which will result in
the inhibition of FOXO-dependent transcriptional activities. Acetylation of
FOXO1 has been associated with the reduction in its activities (Lalmansingh,
Karmakar, Jin, & Nagaich, 2012; Tikhanovich, Cox, & Weinman, 2013). On the
contrary, deacetylation of FOXO1 increases its activities. It has been reported
that members of the sirtuin family of deacetylases, silent information regulator
-1 (Sirt-1) and Sirt-2, increase the transcriptional and DNA binding activities of
FOXO1 via deacetylation. (Kobayashi et al., 2005)
Our lab has shown that there was a significant elevation in FOXO1
DNA binding activities in diabetic fracture calluses. When TNF-α was inhibited
by pegsunercept treatment, FOXO1 nuclear translocation diminished (Alblowi
et al., 2009). Furthermore, high glucose inhibits FOXO1 binding to certain
promoters and causes FOXO1 to elevate the expression of cytokines that
interfere with healing (Zhang et al., 2015).
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Specific Aims:
Diabetes mellitus is a common chronic disease that affects more than 230
million people worldwide. A significant complication of diabetes is impaired
fracture healing (Cozen, 1972; Herskind, Christensen, Norgaard-Andersen, &
Andersen, 1992; Loder, 1988). Long bone fractures heal primarily by
endochondral bone formation. Chondrocytes deposit cartilage to form a soft
callus, which also acts as an anlagen for later bone formation (L. C.
Gerstenfeld et al., 2002). We have proposed that diabetes interferes with
fracture healing by causing premature loss of cartilage through upregulation of
osteoclast activity. This concept was supported by findings that the number of
osteoclasts was doubled in the calluses of diabetic animals in comparison to
the normal animals and coincided with the upregulation of pro-inflammatory
and pro-apoptotic factors including TNF-a (Alblowi et al., 2013; Kayal et al.,
2007).
Based on findings that TNF-a induces FOXO1, we tested the
hypothesis that Foxo1 deletion in chondrocytes will improve the bone
healing in diabetic mice by regulating the expression of a critical proosteoclastogenic factor, RANKL. To investigate whether FOXO1 activation in
chondrocytes is a critical factor in diabetes-impaired fracture healing we
examined mice with lineage-specific deletion of FOXO1 in chondrocytes and
determined the impact on fracture repair in diabetic animals.
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Materials and methods:
Animal model and Induction of diabetes:
Cre recombinase is an enzyme from the integrase superfamily that
uses a mechanism similar to topoisomerase to produce a lineage-specific
recombination. Specifically, it catalyzes the site-specific recombination
between the LoxP sites on both ends. The result of this recombination at the
specific sites depend on the sequence and the location of the LoxP sites. The
DNA that is located between the two floxed sites will be excised which will
drive tissue specific or site specific gene deletion.
All Animal experiments were conducted in conformity with the
University of Pennsylvania Institutional Animal Care and Use Committee. In
the current study lineage-specific FOXO1 deletion in chondrocytes was
obtained by crossing mice with floxed FOXO1 alleles, provided by Ronald
A.DePhino (MD Anderson Cancer Center) as previously described in the
literature (Paik et al., 2007), with mice expressing Cre recombinase under the
control of col2α1 (obtained from the Jackson Laboratory). This breeding
scheme produced the experimental Col2α1Cre+/FOXO1L/L and Col2α1Cre-/
FOXO1L/L which were used as controls. Between two to five mice were housed
per cage under standard conditions with a 14-hours light/ 10-hours dark
cycles. All procedures were done on adult mice between the age of 10-16
weeks. Mice were rendered diabetic by intraperitoneal (I.P) injections of
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streptozotocin (50mg/kg) (Sigma, St. Louis, MO) in 10mM citrate buffer once
every day for 5 consecutive days (Graves et al., 2005). Control mice were
injected with 10mM citrate buffer alone. Blood glucose was measured weekly
from blood obtained from a small laceration in the tail. The weight of the mice
was monitored as well as the mice hydration status. Mice were considered
diabetic when blood glucose levels exceeded 250 mg/dl for two consecutive
measurements. Mice typically become diabetic after 10 days from starting the
injections. If animals did not develop hyperglycemia after the first round of
injections, they were given a second round of STZ and if they still did not
respond they were euthanized. Experiments were carried out when mice had
been diabetics for at least 3 weeks.
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Figure 8: The mouse model and the breeding scheme. An Illustration
of the mouse model and the breeding scheme used in the study utilizing
Cre lox system. Col2α1 promoter was used to drive FOXO1 deletion.
Femoral fracture:
An incision was made lateral to the knee and the tendon for the
quadriceps femoris muscle was pushed medially to expose the articular
surface of the femur. A 27-gauge needle was used to gain access to the
medullary canal and a 30-gauge spinal needle was inserted for fixation. After
suturing the incision, a controlled closed simple transverse fracture was
created by blunt trauma using a guillotine device. The animals were
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euthanized and femurs were harvested at 3 different time points: day 10, day
16, and day 22 post fracture. The fracture sites were evaluated physically and
radiographically at euthanasia time. All the fractures that weren’t middiaphyseal or the grossly comminuted fractures were excluded from the study.
An illustration of the study time line is presented in figure 9.

Figure 9: Study time line illustration showing the animal distribution and the
different study groups.
Micro-Computed Tomography and Image Analysis:
To evaluate the total callus and the bone volume, the fractured femurs
were scanned individually using a desktop micro-computed tomography
system (Scanco µCT40, Scanco Medical, Basserdorf, Switzerland). The scan
axis coincided nominally with the diaphysial axis, 70kVp and 114mA were
used to scan the samples. The integration time was 200ms with 19µm voxel
size. Constrained, 3-D Gaussian filter (sigma=0.8, support=1) was used for
noise reduction. A fixed, global threshold was chosen that represented the
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transition in X-ray attenuation between the mineralized and the unmineralized
tissue. The 3D reconstruction and the image data were analyzed using
software provided by the system manufacturer to quantify the bone volume of
the fracture callus using the same threshold.
Histology and Histomorphometric Analysis:
The harvested femurs with a small amount of surrounding muscle and
soft tissues were fixed for 24 hours in cold 10% paraformaldehyde followed by
decalcification in 10% EDTA (Boston Bioprodicts, Worcester, MA) for 5 weeks.
The internal fixation pin was removed and the samples were then processed in
ascending ethanol concentrations. After processing, the pieces were
embedded in paraffin, sectioned at 4 microns and prepared for staining.
Sectioning and histomorphometric measurements were performed according
to methodologies described in (L. C. Gerstenfeld, Wronski, Hollinger, &
Einhorn, 2005). Cross-sectional transverse sections were sampled along the
long axis of the bone including the fracture site itself. The callus area,
cartilage area, and new bone area were measured in sections stained with
safranin-O/fast green. The area of each tissue was assessed by computer
assisted image analysis using NIS elements AR software (Nikon).
Measurements were made by one examiner under blinded conditions, with the
results confirmed by a second blinded examiner.
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Safranin-O/Fast Green Stain:
Slides were baked, deparaffinaized in xylene and hydrated in graded
ethanol series from 100 to 80% for 2-3 minutes each. To stain the nuclei,
slides were placed in Harris modified hematoxylin (Fisher Scientific, Fair Lawn,
NJ) for 30 seconds then rinsed in slow running water for at least 5 minutes.
Fast green (Fisher Scientific, Fair Lawn, NJ) was used as a background stain.
The slides were placed in the stain for 7 minutes and then rinsed in 1% acetic
acid for 1 second. After that, slides were placed in safranin-O (Sigma-Aldrich,
St. Louis, MO) for 10 minutes to stain the cartilage. This was followed by
dehydration in which slides go through graded series of ethanol from 80 to
100% and then placed in xylene until cover slipping.
Mechanical testing:
A separate set of mice were utilized for mechanical testing. The mice
were euthanized 5 weeks post-fracture to evaluate the mechanical properties
of the broken femur at the remodeling phase. Both the experimental and the
contralateral femurs were harvested. The femurs ends were cemented and
torsional testing was carried out on a servo hydraulic testing machine (MTS
Corp., Minneapolis, MN) using a 20 Nm reaction torque load cell (Interface,
Scottsdale, AZ). Femurs were tested to failure at an actuator head
displacement rate of 1°/second. Max torque, stiffness, toughness, and
modulus of rigidity were tested according to the method described by
Manigrasso and O’Connor 2004. For each parameter, the means and
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standard deviations were calculated.
TRAP staining:
Osteoclast formation was determined by counting the number of
multinucleated, tartrate-resistant acid phosphatase (TRAP) positive cells lining
cartilage. After deparaffinization and hydration, as previously mentioned,
slides were placed in 0.2M acetate buffer for 30 minutes. The buffer was
prepared from 16mg/ml of 0.2M sodium acetate (Sigma-Aldrich, St. Louis,
MO) and 11.6mg/ml of 50mM tartaric acid (Sigma-Aldrich, St. Louis, MO) with
a pH of 5.0. After 30 minutes, 0.5mg/ml naphthol AS-MX phosphate (SigmaAldrich, St. Louis, MO) and 1.1 mg/ml fast red TR salt (Sigma-Aldrich, St.
Louis, MO) were added to the solution and the slides were incubated at 37°C
for 10 to 15 minutes. The slides were then placed in Harris modified
hematoxylin (Fisher Scientific, Fair Lawn, NJ) for 30 seconds to stain the
nuclei and rinsed in slow running water for 5 minutes. Slides were left over
night to dry and cover slipped the next day.
Immunohistochemistry in histological sections:
To confirm the TRAP staining results, sections from formalin-fixed,
paraffin-embedded samples were used for IHC staining using cathepsin K
antibody. Deparaffinization and hydration were performed as mentioned above
and antigen retrieval was performed using pressure cooker (2100-Retriever
Aptum, Southampton, UK) at 120°C with 10mM of citric acid with a pH of 6.0.
Samples were then blocked with avidin-biotin (Vector Laboratories,
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Burlingame, CA) and nonimmune serum matching the secondary antibody.
Slides were then incubated overnight with anti-cathepsin K antibody (Abcam:
AB19027) at 4°C as well as a matched control IgG. The slides were then
rinsed the next day and quenched with 3% hydrogen peroxide and incubated
with biotin labeled secondary antibody (Santa Cruz Biotechnology, Santa
Cruz, CA). Hematoxylin was used as a counter stain followed by slide
hydration and cover slipping. Analysis of the cartilage was performed by
comparison with safranin-O/fast green stained serial sections. Analysis was
done blindly by one examiner with the results confirmed by a second blinded
examiner.
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Immunofluorescence in histological sections:
Paraffin embedded slides were used for in vivo immunofluorescence
assays. After deparaffinization and hydration, pressure cooker (2100-Retriever
Aptum, Southampton, UK) was used at 120°C with 10mM of citric acid with a
pH of 6.0 for antigen retrieval followed by non-specific binding blocking for 55
minutes. Finally, an overnight incubation with anti-RANKL antibody (Santa
Cruz sc9073) or anti-cleaved caspase 3 antibody (Cell Signaling Technology
96615) at 4°C as well as the appropriate isotype-matched negative control
IgG was done. Primary antibody was localised by Biotinylated secondary
antibody (Vector Laboratories). Avidin–biotin peroxidase enzyme complex
(ABC) and tyramide signal amplification (TSA) were used to amplify the
signals. Alexa Fluor 546–conjugated streptavidin (Invitrogen S-11225) was
used to visualize the staining. Finally, the slides were mounted with DAPI
(Sigma-Aldrich). Images were captured at different magnifications (4x, 20x,
and 40x magnification) using a fluorescence microscope (ECLIPSE 90i;
Nikon). The exposure time was set to the experimental group based on the
IgG control signals. The quantification was performed with the aid of NIS
Elements AR image analysis software. The percentage of positive cells was
obtained by dividing the immunopostive cells over the total cell number
measured by DAPI.
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Primary Cell culture:
Primary costal chondrocytes were isolated from (2-4 days old)
experimental Col2α1Cre+/FOXO1L/L and control Col2α1Cre-/FOXO1L/L mice.
Briefly the mice skin was dissected, the ribs were isolated, incubated in
Pronase for 45 minutes to dissolve the soft tissue, followed by 60 minutes in
Collagenase D to dissociate the hard tissue from the remaining soft tissues.
Finally, the rib cage was incubated in Collagenase D for 3-5 hours to release
the cells. Chondrocytes were cultured in DMEM media supplemented with
10% FBS and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific).
All cell cultures were maintained in a 5% CO2 humidified incubator at 37°C.
Cells were put into starvation for 2 days (low serum media) followed by either
serum stimulation for 14 hours or hypertrophic differentiation induction for 4
days using DMEM with 10% FBS supplemented with 10mM βglycerophosphate and 50μg/ml ascorbic acid, RNA extraction was done using
Quick-RNA Microprep kit (Zymo). Real-time quantitative RT-PCR of RANKL
gene was performed.
Reverse Transcription and Real Time PCR:
For a given experiment RNA was isolated from cells and
SYBR® Green reverse transcription reagents (Applied Biosystems, Foster
City, CA) was used for first-strand cDNA synthesis and amplification. Using a
thermocycler, samples were incubated at 37°C for 60 minutes, followed by
95°C for 5 minutes and then held at 4°C until transferred to -20°C for storage.
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Real time PCR was done on StepOnePlus Real-Time PCR System using 10µl
of master mix SYBR® Green gene expression assays (Applied Biosystems,
Foster City, CA). Each experiment was performed three times and the results
from the three separate experiments were combined in order to derive mean
values and standard of error.
In vitro Immunofluorescence:
Primary chondrocytes isolated from Col2α1Cre+/FOXO1L/L and control
Col2α1Cre-/ FOXO1L/L mice were seeded in 96-well plates. They were
incubated in low glucose (5mM d-glucose), high glucose (25mM d-glucose) for
5 days. In another set, cells were incubated with CML-BSA (200μg/ml) for 3
days, which was prepared by chemical modification of BSA (Sigma-Aldrich) as
previously described (Alikhani et al., 2010). The control cells were incubated
with unmodified BSA. The cells were fixed for 10 minutes with 10%
formaldehyde, permeabilized in 0.5% Triton X-100 for 5 min. Non-specific
blocking was done with 2% nonimmune serum matching the secondary
antibody followed by primary anti-RANKL antibody (Santa Cruz sc9073).
Primary antibody was localised with biotinylated secondary antibody and Alexa
Fluor 546–conjugated streptavidin and finally DAPI was used to stain the
nuclei. Images were captured by a fluorescence microscope (Nikon Eclipse Ti)
with the same exposure time for both the control and the experimental group.
The mean fluorescence intensity (MFI) was measured using NIS Elements AR
image analysis software.
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TUNEL Assay:
Apoptotic cells were detected by DeadEnd™ Colorimetric TUNEL
System (Promega, WI, USA) which detects apoptotic cells by labeling and
detecting DNA strand breaks by the TUNEL method. To distinguish apoptotic
chondrocytes from other cells the images were combined with bright-field
channel to confirm the cell morphology. In addition, stain was compared with a
saffranin-o/fast green stain to verify the location of the chondrocytes. Slides
were first depraffinaized and hydrated in the same manner mentioned. Slides
were then incubated at room temperature for 15 minutes in diluted proteinase
K solution and then rinsed with PBS. This was followed by 5 minute incubation
in endogenous oxidation blocking solution, which is 3% hydrogen peroxide, at
room temperature and then rinsed in PBS. After that, slides were incubated at
room temperature for 30 seconds in equilibration buffer, then in working
strength TdT enzyme for an hour at 37°C. Slides were then incubated in
working strength stop/wash buffer for 10 minutes at room temperature, they
were then rinsed in PBS and incubated in anti-digoxignenin conjugate for 30
minutes at 37°C. Slides were rinsed again in PBS and mounted with DAPI to
stain the nuclei.
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Chromatin Immunoprecipitation Assay:
Chromatin immunoprecipitation assays (ChIP) were carried out with
ChIP It Kit (Active Motif) using approximately 1.5 x107 ATDC5 murine
chondrogenic cells. Hypertrophic differentiation was induced for 6 days using
DMEM/F12 media supplemented with 50µg/ml ascorbic acid and 10mM βglycerophosphate. Different groups of cells at 70 to 80% confluency were
separately treated with TNF-α (20ng/ml) for 30 minutes, CML-BSA (200μg/ml)
or unmodified BSA (200μg/ml) as a control for 3 days, and high glucose
(25mM) for 5 days. ChIP was done following the manufacturer’s instructions.
Formaldehyde was used to fix the cells, followed by a PBS wash and glycine
to stop the fixation process. The cells were collected by scraping and pelleted.
A Dounce homogenizer was used to lyse the cells and to release the nuclei.
An enzyme was used to shred the chromatin followed by Anti-FOXO1 antibody
(Santa Cruz Biotechnology, Inc.) or control polyclonal nonspecific IgG (Cell
Signaling, Danvers, MA) incubation. Protein G-coupled beads were used to
precipitate the antibodies. Quantitative real-time PCR for RANKL and
caspase-3 promoter which has a consensus FOXO1 element, was performed
in triplicates.
Luciferase reporter assay:
Transient transfection with luciferase reporter constructs was performed
by senior lab members, Dr Guangyu Dong and Citong Zhang, using
Lipofectamine™ 3000 (Thermo Fisher Scientific) in 48-well plates as

38

described before (Zhang et al., 2015). Briefly, ATDC5 cells were incubated in
low serum culture media for 5 days with 5 or 25mM d-glucose, or with CMLBSA (200µg/ml) for 3 days, or TNF-α (10ng/ml) for 12 hours before running
the assay. Cells were cotransfected with RANKL luciferase reporter (provided
by Dr. Charles A. O’Brien, University of Arkansas for Medical Sciences, Little
Rock, AR) (O'Brien, Kern, Gubrij, Karsenty, & Manolagas, 2002) or Caspase-3
reporter together with pGL3 luciferase control vector, FOXO1ADA or
(Addgene) plasmid (referred to FOXO1) that is constitutively transported to the
nucleus, pcFOXO1 which is a wild type FOXO1, or pCMV control plasmid.
Two days after transfection, cells were lysed, Firefly and Renilla luciferase
activities were measured using Dual Luciferase Reporter Assay kit (Promega)
according to the manufacturer’s instructions. Firefly luciferase activities were
divided by Renilla activities to normalize for transfection efficiency.
Experiments were performed two to three times with similar results.
The role of FOXO1 in chondrocytes proliferation and differentiation:
The number of proliferative and hypertrophic chondrocytes was counted
in the healing callus in Saf/O stained slides to measure the cell density.
Furthermore, Primary chondrocytes were extracted from experimental FOXO1
deleted and normal WT neonates. Cells were incubated in serum free media,
stimulated with serum for 14 hours and the expression of cell cycle genes was
determined by quantitative qPCR. Another set of cells were used to measure
the proliferation curve. Cells were grown for 5 days, live images were taken
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every day and finally DAPI was used to stain the nuclei. The number of cells
was quantified at each time point.
To study the effect of FOXO1 on chondrocytes differentiation, primary
cells were treated with differentiation media for 4 and 10 days, quantitative
qPCR were performed to detect the expression of known differentiation
markers. Another set of cells were cultured and Alician blue staining was
performed at 0,4,7, and 14 days to evaluate the matrix formation abilities of
the cells. The absorbance of the dye was detected using TECAN odometer.

FOXO1 binding activities and nuclear translocation: ( ongoing
experiment)
To better understand how high glucose regulates FOXO1 activations.
ATDC5 murine chondrogenic cells will be seeded in 6-well and 96-well plates.
Hypertrophic differentiation will be induced using DMEM/F12 media
supplemented with 50µg/ml ascorbic acid and 10mM β-glycerophosphate.
Cells will be incubated in high glucose containing media with the use of the
following; insulin, AKT inhibitor, TLR4 inhibitor, Sirt-1 inhibitor, HDAC inhibitor,
N-Acetyl-L-cysteine, and L-NAME hydrochloride. To explore the effect of
insulin, phosphorylation, acetylation and ROS on FOXO1 activation under high
glucose conditions.
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Nuclear protein will be extracted from the 6-well plates, and will be used to
evaluate FOXO1 binding activities using FOXO1 Transcription Factor Assay
Kit (Abcam).
The 96-well plates will be used for immunostaining with FOXO1 antibody
compared to matched IgG control. FOXO1 nuclear localization will be
quantified.
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Statistics:
Statistical analysis between the groups were determined by analysis of
variance, one-way ANOVA, Tukey’s post-hoc test to denote significance. P <
0.05 was considered statistically significant. All the results are expressed as
the mean ± SEM. (*) indicates a significant difference between normal and
diabetic (P<0.05). (+) indicates a significant difference between the diabetic
animals with FOXO1 deletion and the diabetic control group (P<0.05).
For the in vitro experiments, Student’s t test was used for the
comparison between the study groups. P < 0.05 was considered statistically
significant.
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RESULTS
Diabetes validation:
To establish that the animals were diabetic, blood was obtained from
the tail of the animal and blood glucose was measured. The experimental
group, which was treated with streptozotocin, had a mean blood glucose level
of 322 mg/dl (STD ±58), while the control group, which had the vehicle alone,
had a mean blood glucose level of 85 mg/dl (STD ±10). This indicates that the
experimental group was rendered diabetic by streptozotocin and the control
group remained normoglycemic. In addition, the blood glucose level was also
measured at the euthanasia time to confirm the established findings.
Validating the animal model:
To confirm the presence or absence of Cre recombinase in the animals,
genotyping was performed via PCR using both Cre and FOXO1 primers.
Genomic DNA was obtained from the mice’s ears/tails before starting the
experiment and the results were validated at the time of euthanasia.
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Figure 10: Col2a1Cre deletes FOXO1 in Chondrocytes only.
(A) Electrophoresis of PCR amplified FOXO1 and Cre recombinase primers
to establish genotyping for each animal. (B) Immunofluorescence of primary
chondrocytes using Col2 specific antibody to confirm the cells’ phenotype. (C)
Immunofluorescence staining of primary chondrocytes from WT and (D)
FOXO1 deleted mice using FOXO1 specific antibody to confirm that the
experimental chondrocytes didn't’ express FOXO1. (E) In vivo
Immunofluorescence staining of fractured callus from both WT and FOXO1
deleted mice using FOXO1 specific antibody to show the lineage-specific
deletion. * indicates a significant difference between WT and FOXO1 deleted
group using Students t-test. P<(0.05).
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Histomorphometric Analysis:
Experiments were carried out focusing on the stage of cartilage
removal and bone formation, days 10, 16, and 22 during fracture repair. Callus
size and cartilage area were measured on transverse sections of fracture
midline stained with safranin-O/fast green stain. The histomorphometric
analysis of fracture callus showed that there was no significant difference
between the cartilage areas of the normoglycemic, diabetic, and diabetic mice
with FOXO1 deletion in chondrocytes 10 days post fracture (P>0.05). On day
16, the diabetic group had 77% less cartilage than the normoglycemic group
(P<0.05), and FOXO1 deletion in chondrocytes of the diabetic animals
increased the cartilage area by 369% (4.7 fold) (P<0.05) to match the values
of the normoglycemic group (P>0.05; Figure 11).
To evaluate the significance of premature cartilage resorption on the
callus, the callus size and new bone formed area were measured. Fracture
calluses of the diabetic control group were 43% smaller on day 16 and 37%
smaller on day 22 compared to the normoglycemic control group(P<0.05).
FOXO1 deletion in chondrocytes in diabetic animals significantly increased the
callus size on day 16 by 64% and on day 22 by 52% when compared to
diabetic control groups (P<0.05). This parameter was comparable to that of
normoglycemic animals (P>0.05; Figure12). Newly formed bone area was also
quantified histologically. Diabetes decreased new bone formation by 47% on
day 16 and by 51% on day 22(P<0.05). FOXO1 deletion from the diabetic
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animals increased the new formed bone areas at day 16 by 77% and at day
22 by 96% (P<0.05) and this was comparable to that of normoglycemic groups
(P>0.05; Figure 12).
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Figure 11: Diabetes significantly reduces cartilage area prematurely,
which is rescued by FOXO1 deletion in chondrocytes. Comparison of
cartilage area between (A) normoglycemic, (B) diabetic control, and (C)
diabetic with FOXO1 deletion using safranin-O/fast green stained sections to
measure the area of cartilage within each callus. Data are expressed as mean
± SEM. * indicates a significant difference between normal and diabetic
(P<0.05). + indicates a significant difference between the diabetic animals with
FOXO1 deletion and the diabetic control group (P<0.05)
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Micro CT:
The differences in callus size and bone formation in on day 16 and 22
were confirmed by high-resolution µCT. On day 16 post fracture, the total
callus volume of the diabetic group was 39% smaller and the bone volume
was 29% smaller compared to the normoglycemic group (P<0.05). On the
other hand, FOXO1 deletion from chondrocytes in diabetic animals increased
the total volume by 59% and the bone volume by 33% (P<0.05), to volumes
similar to that of the normoglycemic group (P>0.05). The same trend was
observed on day 22. When compared to the normal group, the diabetic group
had 41% smaller total volume and 34% smaller bone volume (P<0.05). Upon
FOXO1 deletion in the diabetic group, the total volume increased by 65% and
the bone volume increased by 57%(P<0.05) to match the normoglycemic
group (P>0.05; figure 12)
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Figure 12: Premature cartilage resorption caused by diabetes resulted in
significantly smaller callus and bone volume. FOXO1 deletion rescued
the callus and the bone volume to normal levels. Comparison of callus size
and new bone formation in in (A) normoglycemic, (B) diabetic control, and (C)
diabetic with FOXO1 deletion using µCT scans and histology. The callus was
defined as the area within the peripheral fibrous capsule, excluding the original
cortical bone. Data are expressed as mean ± SEM. * indicates a significant
difference between normal and diabetic (P<0.05). + indicates a significant
difference between the diabetic animals with FOXO1 deletion and the diabetic
control group (P<0.05)
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Mechanical testing:
To evaluate if the quality of the healed femurs is different among the
study group, torsional mechanical testing was performed on a separate set of
mice. The contralateral (non-fractured) legs were tested first, the results show
that the base line values of both diabetic groups were identical. However, the
mechanical testing of the experimental side showed that the diabetic control
mice had significantly lower maximum torque to failure strength, stiffness,
toughness, and modulus of rigidity compared to normal control mice. FOXO1
deletion restored the max torque, the stiffness, and the modulus of rigidity to
levels comparable to the normal control.
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Figure 13: Diabetes significantly alters the mechanical strength of the
healing callus. FOXO1 deletion restored the strength to normal levels.
(A) Comparison of callus strength using torsional mechanical testing revealed
that both diabetic groups had similar base line values. (B) Diabetic control
mice had significantly lower maximum torque to failure strength, stiffness,
toughness, and modulus of rigidity compared to normal control mice. FOXO1
deletion restored the max torque, the stiffness, and the modulus of rigidity to
levels comparable to the normal control. Data are expressed as mean ± SEM.
* indicates a significant difference between normal and diabetic (P<0.05). +
indicates a significant difference between the diabetic animals with FOXO1
deletion and the diabetic control group (P<0.05)
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Osteoclasts:
In order to further investigate the process of cartilage resorption, the
number of osteoclasts lining cartilage was measured on transverse callus
sections stained with TRAP. The diabetic group had 2.8 times more TRAP
positive cells lining cartilage than the normoglycemic group on day 10
(P<0.05). The Diabetic group with FOXO1 deletion in chondrocytes had 4.5
times less TRAP positive cells than the diabetic control group (P<0.05; Figure
14). Furthermore, immunohistochemical staining using cathepsin K specific
antibody was used to validate the osteoclast numbers obtained from TRAP
stain. Ten days post fracture, the diabetic group had 4.4 times more cathepsin
K positive cells lining cartilage than the normoglycemic group. Diabetic group
with FOXO1 deletion in chondrocytes had 6.5 times less cathepsin K positive
cells than the diabetic control group (P<0.05; Figure 14).
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Figure 14: Diabetes significantly increases osteoclasts formation,
FOXO1 deletion reduced the osteoclasts numbers to normal level.
Comparison of osteoclast numbers in (A,B) normoglycemic, (C)diabetic
control, and (D) diabetic with FOXO1 deletion using TRAP stained sections.
The obtained results were confirmed with cathepsin K IHC staining. Data are
expressed as mean ± SEM. * indicates a significant difference between normal
nd diabetic (P<0.05). + indicates a significant difference between the diabetic
animals with FOXO1 deletion and the diabetic control group (P<0.05).
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In vivo RANKL:
To provide an insight into how FOXO1 expression by chondrocytes may
regulates osteoclasts activation, quantitative analysis was performed to
evaluate RANKL expression in chondrocytes by immunofluorescence using
RANKL specific antibody compared to control IgG antibody. Diabetes led
to 1.9-folds increased in the percentage of RANKL positive chondrocytes on
day 10 and 1.7-fold increase on day 16 post fracture compared to the
normoglycemic control group. On day 10 post fracture FOXO1 deleted group
had 9 times less RANKL positive chondrocytes and on day 16 they had 23
times less RANKL positive chondrocytes compared to the diabetic group
(P<0.05; Figure 15). Those results indicate that diabetes enhances
chondrocytes RANKL expression in the fracture calluses and the expression
was mediated by FOXO1.
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Figure 15: Diabetes increases chondrocytes’ RANKL expression which is
FOXO1 dependent. Immunofluorescence images from (A) normoglycemic,
(B)diabetic control, and (C) diabetic with FOXO1 deletion using RANKL
specific antibody to evaluate the Chondrocytes’ RANKL expression in the
fracture callus. (D,E) Quantitative data from day 10 and 16 post fractures. (HZ)
Hypertrophic zone. Data are expressed as mean ± SEM. * indicates a
significant difference between normal and diabetic (P<0.05). + indicates a
significant difference between the diabetic animals with FOXO1 deletion and
the diabetic control group (P<0.05). # indicates a significant difference
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between the diabetic animals with FOXO1 deletion and the normal group. **
indicates a significant difference between the WT and FOXO1 KO.
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In vitro RANKL expression :
To investigate whether FOXO1 regulates RANKL expression in
chondrocytes under diabetic conditions, primary chondrocytes were isolated
from experimental Col2α1Cre+/FOXO1L/L and from control Col2α1Cre-/
FOXO1L/L newborn mice. The cells were cultured and quantitative qPCR
analysis of RANKL mRNA levels was carried out after serum stimulation and
differentiation induction. Chondrocytes with FOXO1 deletion had 46% less
RANKL mRNA level at base line, 37% less RANKL expression after 14 hours
of serum stimulation, and 54% less RANKL expression after 4 days of
hypertrophic differentiation induction.
Another set of isolated cells were incubated in high glucose and advanced
glycation end product followed by immunofluorescence staining using RANKL
specific antibody. Under high glucose condition, control group showed 62%
increase in RANKL mean fluorescence intensity, FOXO1 deleted group
showed 85% reduction in RANKL expression under low glucose and 69%
reduction under high glucose treatment. Similar to the high glucose conditions,
incubation with AGE led to 61% increase in RANKL expression in the control
group compared to serum control incubation, FOXO1 deletion reduced RANKL
expression by 82% under AGE incubation (Figure 15).
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Figure 16: In vitro diabetic conditions increase chondrocytes’ RANKL
expression which is FOXO1 dependent In vitro RANKL expression was also
evaluated using primary chondrocytes, isolated from control mice (WT) as well
as experimental FOXO1 deleted mice (FOXO1 KO), treated with low glucose
(LG) and high glucose (HG) containing culture media. Another set of cells
were treated with advanced glycation end product (AGE) or unmodified bovine
serum albumin. To better understand how FOXO1 modulate osteoclast
formation by regulating chondrocytes’ RANKL expression. Primary
chondrocytes precursor were isolated from Col2a1Cre+/FOXO1L/L (FOXO1
KO) and from the wild type (WT) Col2a1Cre -/FOXO1L/L stimulated with serum
for 14 hours or cultured in chondrogenic media to induce chondrogenic
differentiation for 4 days as described in the materials and methods sections.
(A) Quantitative RT-PCR analysis of RANKL mRNA levels at different time
points. Data are expressed as mean ± SEM. * indicates a significant difference
between WT and FOXO1 deleted group using Student T test (P<0.05).
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Luciferase reporter, and ChIP assays:
To verify the association and the possible regulation of RANKL by
FOXO1, a luciferase reporter and ChIP assays were carried out. For the
Luciferase reporter, ATDC5 cells were cotransfected with either FOXO1
plasmid (FOXO1ADA) or vector. TNF-α, AGE, and high glucose doubled the
RANKL luciferase relative expression with FOXO1 plasmid compared to the
vector control. (Figure 17).
In addition, Chromatin immunoprecipitation (ChIP) assays showed that
FOXO1 interacted with the RANKL promoter under diabetic conditions. High
glucose resulted in 10-fold enrichment of FOXO1 association with the RANKL
promoter compared with control IgG precipitates. In addition, AGE resulted in
13-fold, and finally TNF-α resulted in 33-fold enrichment. (Figure 17).
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Figure 17: Chondrocytes’ FOXO1 modulates diabetic fracture
healing by regulating RANKL expression (A) The interaction of the
RANKL promoter and FOXO1 was determined by quantitative real-time
PCR of the pulled down chromatin using anti-FOXO1 IgG compared to
matched control IgG. (B) RANKL luciferase reporter assay after
cotransfection with control (vector) or FOXO1 plasmid (FOXO1ADA).
Data are expressed as mean ± SEM. * indicates a significant difference
between (IgG and FOXO1antibody), and between (control vector and
the FOXO1ADA) using Student’s T test (P<0.05).
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Chondrocytes Apoptosis & cartilage degradation:
To test wither premature cartilage resorption was the only mechanism
of early cartilage loss in diabetic animals, chondrocytes apoptosis was
measured using TUNEL assay was conducted at day 16 post fracture. In
addition, cleaved caspase-3 expression by chondrocytes was detected using
immunostaining. Finally, ChIP and luciferase reporter assays were performed
using ATDC5 cells under different in vitro diabetic conditions to study the
association between FOXO1 and caspase-3 promoter. We found that the
number of apoptotic chondrocytes was significantly higher in the diabetic
group compared to the normoglycemic. FOXO1 deletion reduced the number
of apoptotic chondrocytes to normal levels. Furthermore, diabetic animals has
50% more chondrocytes expressing caspase-3 compared to normal animals.
FOXO1 deletion completely blocked the up-regulated expression of caspase-3
caused by diabetes. In vitro experiment shows that there is a significant
increase in FOXO1 binding activities to caspase-3 promoter under high
glucose treatment and AGE treatment compared to IgG control. Finally, the
luciferase reporter assay shows that FOXO1 regulates caspase-3 expression
under in vitro diabetic model.
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Figure 18: Diabetes significantly increases chondrocytes apoptosis and
caspase-3 expression during fracture healing. FOXO1 deletion reduces
both parameter to normal levels. (A) An immunofluorescence images of the
IgG control. (B) An immunofluorescence images of the experimental group
using TUNEL assay. (C) Quantified data showing that diabetic control mice
has around 50% increase in apoptotic cells compared to normal group.
FOXO1 deletion reduced it to normal levels. (D) An immunofluorescence
pictures of the IgG control. (E) An immunofluorescence pictures of the
experimental group using cleaved caspase-3 antibody. (F) Quantified data
showing that diabetic control group has around 50% increase in caspase-3
expressing chondrocytes compared to the normal group. FOXO1 deletion
rescued caspase-3 expressing cells to levels similar to the normal group. (G)
ChIP and Luciferase reporter assay shows that both high glucose containing
media (HG) and AGE increases FOXO1 binding activities to Caspas-3 as well
as regulating its expression at the transcriptional level.
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The role of FOXO1 in chondrocytes proliferation and differentiation:
The number of hypertrophic and proliferative chondrocytes was
determined in the healing callus by counting the cells in Safranin-O stained
sections. The number of cells was normalized by the measured area. FOXO1
deletion significantly increased the number of the proliferative, but not the
hypertrophic, chondrocytes in the healing callus.
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Figure 19: FOXO1 deletion increases the number of proliferative
chondrocytes in the healing callus. (A) The quantified data shows that
FOXO1 deletion increases the number of proliferative chondrocytes compared
to the normal control, in addition, FOXO1 deletion in diabetic animals
increased the proliferative count over the wild type diabetic control. (B) The
number of hypertrophic chondrocytes was no statistically different between the
study groups.
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Primary chondrocytes proliferation curve:
WT and cKO cells were grown in DMEM with 5% FBS in 96-well plate
pictures were taken for live cells during 0-4day and then fixed on the 5th day
and stained with DAPI.
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Figure 20: FOXO1 deletion enhances chondrocytes proliferation (A) An
image of DAPI staining of primary chondrocytes isolated from both
experimental (FOXO1 KO) and wild type control (WT) after 5 days in culture.
(B) The proliferation curve of the primary cells shows a significant increase in
cell proliferation upon FOXO1 deletion.
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The expression of cell cycle genes in primary chondrocytes:
To better understand how FOXO1 deletion increases chondrocytes
proliferation. Primary costal chondrocytes were isolated from both the
experimental mice and wild type control. The expression of different cell cycle
genes after 48 hours of cell starvation followed by 14 hours stimulation with
10%FBS was evaluated using quantitative real time PCR.

Figure 21: FOXO1 deletion enhances chondrocytes proliferation via
regulating cell cycle genes expression. qPCR results show the effect of
FOXO1 on cell cycle gene expression. FOXO1 deletion decreases the
expression of p21, p27 which are a potent down-regulator for cells
proliferation. In addition, FOXO1 deletion significantly up-regulated CD1, CD2,
and CDK1, which are critical phosphorylation of variety of proteins, leads to
cell cycle progression.
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The role of FOXO1 in chondrocytes differentiation:
Primary costal chondrocytes from experimental mice and wild type control
were isolated, cultured, and differentiated with differentiation medium (growth
medium supplemented with 50 μg/ml ascorbic acid and 0.5 mM NaH2PO4).
mRNA levels of differentiation genes were detected using qPCR.
Alcain Blue staining was used for another set of cell to detect the matrix
formation at different time points 0day, 4days, 7days, and 14days. The results
show that FOXO1 deletion has no effect on chondrocyte differentiation or
matrix formation ability.
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Figure 22: (A) qPCR results show that FOXO1 deletion doesn’t alter the
expression of different known differentiation markers. (B) Alician blue staining
at different time point for both the experimental and the control group that
shows similar matrix forming abilities. (C) Quantified data from the odometer
shows comparable absorbance at all the studied time points.

77

Discussion

Diabetes is a significant disease with many complications, particularly if
left uncontrolled. It has been reported that diabetes negatively affects the
skeleton integrity and it impairs fracture healing process (Clarke, 2010; Saller,
Maggi, Romanato, Tonin, & Crepaldi, 2008). STZ induced diabetes
significantly affected the calluses in the current investigation. There was a
significant reduction in the cartilage area at the transitional time point, which
resulted in a significantly smaller callus volume and smaller bone volume
within the healing callus. Several parameters were compared by Botolin and
McCabe between STZ induced diabetic mice and non-obese diabetic (NOD)
mouse model which develops type 1 diabetes mellitus spontaneously. Both
animal models showed comparable bone character, and they both showed a
reduction in bone trabeculation with increased marrow adipocytes. They also
showed a similar reduction in osteocalcin mRNA in the tibia. (Botolin &
McCabe, 2006). Furthermore, BB rats, which develop type 1 diabetes
spontaneously, exhibited a comparable decrease in serum osteocalcin levels,
bone mineral density, and mechanical properties to STZ induced diabetic mice
(J Verhaeghe et al., 1989; J. Verhaeghe et al., 1990). Those findings validate
the effect of multiple low dose STZ diabetic model on bone.
The mechanism of how diabetes impairs the fracture healing is not
entirely understood. It has been previously reported that the diabetic animals
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had significantly smaller calluses than those in normal animals. Those
investigations attributed the reduction in size to decreased cartilage and bone
formation (Gooch, Hale, Fujioka, Balian, & Hurwitz, 2000; Topping, Bolander,
& Balian, 1994; Tyndall, Beam, Zarro, O'Connor, & Lin, 2003). In our
investigation, there was no significant difference in the cartilage areas of the
study groups 10 days post fracture, which suggests that diabetes doesn’t
significantly alter the cartilage formation phase. This finding was consistent
with what was reported by Kayal et al, in regards to the expression of collagen
I, II, or X which wasn’t significantly different between normal mice and diabetic
controls which suggests that the overall anabolic rate of chondrocytes or
osteoblasts is similar at that stage.
Cartilage is critical for fracture healing because it acts as a stabilizer for
the fractured bony segments maintaining their close proximity. It also acts as a
template for bone deposition as well as providing essential cytokines,
chemokines, and growth factors. In the current study, diabetic animals
exhibited significantly smaller cartilage areas at day 16, which is a critical time
point for the transition of the healing callus from cartilage to bone, compared to
normal animals. The cartilage areas were restored to normal levels upon
FOXO1 deletion in the diabetic animals. The histology and micro CT of both
day 16 and 22 in this study showed the impact of premature cartilage
resorption caused by diabetes on the fracture healing. Diabetic animals
showed significantly smaller calluses and bone volumes compared to normal
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animals, which was consistent with the finding of Kayal et al. and Alblowi et al.
FOXO1 deletion in diabetic animals rescued both the callus and the bone
volumes to normal levels. We can attribute those changes to the significantly
smaller cartilage area in the diabetic mice at the transitional time point. Naik et
al. showed that there was delayed fracture healing in old mice and it was
associated with smaller cartilage areas in comparison to the young mice (Naik
et al., 2009). Besides, insulin resistant mice with impaired fracture healing
exhibited premature chondrocyte differentiation which resulted in smaller
cartilage areas and subsequently smaller calluses (Shimoaka et al., 2004). On
the other hand, FOXO1 deletion from chondrocytes in diabetic animals in our
study resulted in the maintenance of the cartilage at the transitional time and
led to a better overall healing assessed both radiographically and
histologically.
Inflammation is essential for normal long bone fracture healing but it is
very important to be critically regulated temporally and spatially. The first stage
of the healing process involves an inflammatory response which is critical for
attracting cells and releasing certain molecules essential for the progression of
the healing process. Furthermore, inflammation is also critical at the late bone
remodeling phase which is highly regulated by the expression of IL-1 and IL-6
(Kon et al., 2001). Kayal et al. reported that these cytokines were elevated at
the transitional time point (day 16) which is the period of cartilage resorption,
not the bone remodeling. This confirms the uncontrolled inflammatory status of
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the diabetic calluses compared to normoglycemic and FOXO1 deleted mice. It
is well established that inflammation is associated with increased osteoclast
recruitment and bone resorption (Kindle, Rothe, Kriss, Osdoby, & CollinOsdoby, 2006; Yu, Huang, Collin-Osdoby, & Osdoby, 2004). Many studies
have reported that diabetes was associated with increased
osteoclastogenesis. Suzuki et al. reported that patients diagnosed with DM
had higher TRAP serum level in comparison to healthy individuals. They have
also indicated that those diabetic patients had higher concentrations of Type 1
Collagen Cross-linked Carboxy-terminal Telopeptide in their urine which
confirms the increased resorption rate. (Suzuki et al., 2005). Maes and their
group have shown that the cartilage was not effectively removed when the
number of osteoclasts decreased during endochondral ossification (Maes et
al., 2006). The opposite was observed in the current investigation, the diabetic
animals had higher osteoclasts and cathepsin K positive cells lining cartilage
consistent with the accelerated cartilage resorption observed in the diabetic
animals. Our lab has also previously reported that there was an increase in
TNF-α, MCSF, and RANKL in diabetic fracture healing (Kayal et al., 2007).
These cytokines have been shown to induce the differentiation of bone
marrow hematopoietic precursor cells into bone-resorbing osteoclasts
(Cappellen et al., 2002). It has been shown that diabetes upregulates the TNFα related protein (TRAIL). TRAIL enhances chondrocyte apoptosis and it
blocks osteoclast inhibition effect of OPG (Emery et al., 1998). Furthermore,
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TNF-α stimulates the osteoblast expression of both MSCF and RANKL which
will indirectly activate the osteoclastogenesis (Cenci et al., 2000; Kaplan,
Eielson, Horowitz, Insogna, & Weir, 1996). Our lab previously examined the
mechanism of how diabetes accelerates cartilage resorption through mRNA
profiling and GSEA during the cartilage resorption stage of fracture healing.
We have found that diabetes upregulated couple of TNF-α dependent
inflammatory pathways which were associated with activation and maturation
of osteoclasts (Alblowi et al., 2009). Those inflammatory pathways were
mediated in part by FOXO1. FOXO1 deletion from chondrocytes in the current
investigation resulted in the reduction of the number of osteoclasts lining
cartilage as well as cathepsin K positive cells. This reduction of
osteoclastiogenesis resulted in preserving the cartilage for a longer time to set
the stage for bone deposition.
MMP13 is one of the matrix metalloproteinases superfamilies. Its active
enzyme is collagenase 3 which is secreted in its inactive form. It gets activated
when its pro-domain cleaved. It has been reported that MMPs are involved in
the breakdown of the extracellular matrix of cartilage and, to a lesser extent,
bone, which can be explained by the superior ability of this gene to cleave type
II collagen more efficiently than types I and III. Kayal et al. have previously
reported that there was no difference between normoglycemic and diabetic
animals in mRNA levels of MMP13 at the transitional time point (day 16),
which is highly expressed during fracture healing and plays a major role in
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cartilage remodeling (E. R. Lee, 2006; Yamagiwa et al., 1999) This finding
might indicate that the quality of the cartilage was not affected by diabetes and
the increased osteoclastic activities were the dominant mechanism explaining
the accelerated cartilage lost observed in diabetic animals.
It has been also reported that different inflammatory cytokines are
involved in osteoclast activation. However, RANKL/OPG ratio was suggested
to have the most and the final influential effect. (Hofbauer & Heufelder, 2001).
The accelerated cartilage resorptions in the current investigation may be
explained mechanistically by the increased number of osteoclasts in the
healing callus which was directly proportional to the expression of RANKL by
chondrocytes. Diabetic animals had almost 2 times more chondrocytes
expressing RANKL in the healing callus compared to the
normoglycemic control group. There was almost complete shutdown of
RANKL expressions by chondrocytes upon FOXO1 deletion at all time points
which indicate that RANKL expression was mediated by FOXO1 in the
fractured callus. Gerstenfeld et al. also showed an increase of the residual
cartilage in the healing callus when inflammation was inhibited by nonselective anti-inflammatory drugs (L. C. Gerstenfeld et al., 2007). Thus, the
retention of the cartilage by FOXO1 deletion in diabetic animals can be
mechanistically explained by the reduction in the up-regulated inflammatory
signals caused by diabetes, the reduced inflammatory status rescued the
osteoclasts numbers to normal levels
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The mechanism of diabetes and the lack of insulin during fracture
healing has been controversially discussed in the literature. Our lab has
previously shown that treating diabetic animals with insulin restored normal
fracture healing on both tissue and molecular levels. Since insulin treatment
resulted in significantly larger calluses and bone areas compared to noninsulin treated diabetic animals. In addition, the osteoclastic activities, as well
as tissue degradation markers were all significantly reduced to normal level
upon insulin treatment. This was suggestive that the defect in healing process
noticed in diabetes was a direct result of hyperglycemia. The anabolic effect
on both bone and cartilage has been proposed by many groups. (Thrailkill et
al., 2005). The negative impact of diabetes on the healing calluses were
completely blocked by Gandhi and colleagues upon injecting insulin locally to
the fractured bone (Gandhi, Beam, O'Connor, Parsons, & Lin, 2005).
Nevertheless, local insulin delivery might be mediating its effect via
upregulating IGF-1 activities, which is a potent stimulator for both bone and
cartilage formation and does not necessarily represent the physiologic
conditions (Irwin et al., 2006). Our results are also in agreement with this
finding since both the diabetic control animals and the diabetic mice with
FOXO1 deletion both lacked insulin, however the reduction in the inflammatory
status mediated through FOXO1 deletion restored the impaired healing to a
normal level.
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The direct relationship between BMD and the mechanical loading on
the skeleton is well established. The focus of the current investigation was
directed toward better understanding and studying the effect of T1DM on
bone. Individuals with T1DM are usually associated with nutritional deficits,
low body weight, and lower BMD. In contrary to TIDM, women and men
diagnosed with T2DM usually have normal to high BMD in comparison to
matched non-diabetic individuals. (Rakic et al., 2006; van Daele et al., 1995).
People with lower Body Mass Index (BMI) have a higher risk of developing
osteoporosis in addition to their increased fracture risk compared to matched
peers. The increased BMD in patients with T2DM could be explained as a
biomechanical adaptation of their body to the higher load they are subjected to
since patients withT2DM have higher lean mass and higher weight compared
to matched control. This biomechanical strain can induce bone formation in
patients with T2DM.(Travison, Araujo, Esche, Beck, & McKinlay, 2008). As
mentioned earlier, insulin is considered a potent anabolic factor for cartilage
and bone formation, the hyperinsulinemic states observed in individuals with
T2DM can also enhance the bone formation and will lead to increased BMD
(Barrett-Connor & Kritz-Silverstein, 1996; Thrailkill et al., 2005). Adults
diagnosed with T2DM are at higher risk of fracture despite their higher BMD.
The mechanism is yet not fully understood. Diabetes is associated with a state
of constant and chronic multisystem disruption. The changes in homeostatic
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regulation might have a detrimental effect on bone and skeleton. The
upregulation in the AGE’s could disturp the collagen cross-linking and alter the
bone structure (Saito & Marumo, 2010; Viguet-Carrin et al., 2006; X. Wang,
Shen, Li, & Agrawal, 2002). Furthermore, bone turnover cycles might also be
affected which will alter the microstructure of the bone marrow. Altered marrow
might negatively impact the proliferation of MSC and their capability to
differentiate into bone forming osteoblasts rather than adipocytes. It is well
known that multiple factors regulate differentiation and maturation of MSC into
its committed lineage(Sethe, Scutt, & Stolzing, 2006; S. Zhou et al., 2008).
The swings in anabolic, catabolic, hormonal, and inflammatory status
associated with diabetes could negatively impact MSC’s integrity which will
increase the fragility of bones.(Cramer et al., 2010; Kassem, 1997; Kume et
al., 2005) Thus, the bone mineral density should not be used solely to assess
the fracture risk associated with diabetic patients.
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Figure 23: Possible mechanisms of how type 2 diabetes might increases
bone fragility and fracture risk.
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Long bones are not the only bones associated with increased
osteoclastogenesis, but also the alveolar bone, which supports the teeth in the
mouth, had a higher resorption rate associated with diabetic animals
compared to normal animals (Kohsaka, Kumazawa, Yamasaki, & Nakamura,
1996; Villarino, Sanchez, Bozal, & Ubios, 2006). There was an upregulation in
TNF-α, IL-1β, and the chemokine monocyte chemotactic protein 1 (MCP-1) in
the serum and gingival crevicular fluid of patients with diabetes and they were
associated with more severe periodontitis. Ligature-induced periodontitis is a
well-established model to study periodontal disease. In this model, diabetic
mice had a stronger and prolonged inflammation associated with increased
osteoclastic activities, larger eroded bone area, reduced bone formation (Liu et
al., 2006). Upregulated osteoclastogenesis was shown on a molecular level in
a diabetic periodontal animal model. (Mahamed et al., 2005).
Apical periodontitis (AP) is an inflammatory lesion which surrounds the roots of
the teeth. It is caused by microbial invasion to the root canal system. The
primary goal of any Endodontic therapy is the prevention or the treatment of
AP. The prevalence of individuals with AP associated with at least one tooth
was reported be around 40-50%.(Saunders & Saunders, 1998). It has been
reported that diabetic animals develop larger AP than non-diabetic controls.(A.
Fouad, Barry, Russo, Radolf, & Zhu, 2002). In addition, human studies
indicated a delayed healing of the AP lesions in diabetic individuals compared
to normal individuals.(A. F. Fouad & Burleson, 2003). The mechanism of how
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diabetes facilitates the development of AP or how it retards the healing has not
been thoroughly investigated. This study might open the door to study possible
different pathways and mechanisms using an STZ-induced diabetic animal
model. The role of FOXO1, RANKL, and TNF-α in the development and
healing of AP in diabetes will be my primary research interest in the near
future.
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CONCLUSIONS:
v Diabetes has a significant effect on fracture healing by enhancing
premature cartilage removal via up-regulating the osteoclastic activities.
v Premature cartilage resorption resulted in smaller calluses and bone
volume at later time points.
v Chondrocytes are a major source of RANKL which was FOXO1
dependent.
v Lineage specific FOXO1 deletion down-regulated the
osteoclastogenesis in diabetic animals to normal levels and the
premature loss of cartilage was completely reversed.
v We demonstrated, for the first time, that all the negative impacts from
diabetes on callus size and bone formation were completely blocked
when the cartilage was maintained to the right time. Furthermore, this is
the first time it has been shown that FOXO1 modulates RANKL levels,
which led to alteration in the up-regulated osteoclastogenesis.
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Supplemental Experiments
The role of FOXO1 deletion in the development and the maturation of the
growth plates:
To study if the cartilage phenotype observed during fracture healing in the
diabetic is specific to the cartilage forms during the healing process and not
other types of cartilage, the growth plates of 7 days post-natal mice as well as
adult mice were studied using Safranin/O fast green stain. The adult joint
spaces were also scanned using high resolution micro CT to evaluate the
bone volume and the total growth plate volume.
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Supplemental Figure 1: (A,B) Safranin/O staining of a representative
samples from both normal and FOXO1 deleted neonate. (C) FOXO1 deletion
didn’t change the growth plates zones.
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Supplemental Figure 2: (A) Safranin/O staining of a representative samples
from both normal and FOXO1 deleted adult growth plates. The images shows
no difference in the orientation of the chondrocytes and the size of the growth
plates between both groups (B) Micro CT images for femoral heads that
shows comparable sizes between the WT and FOXO1 deleted mice. (C)
Quantified data showing no differences in the total volume (TV) and bone
volume (BV) (D) Tibial plateau μ CT image and quantified data shows no
significant difference between the study groups.
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Ongoing experiments
Collaborative work with Dr. Dodge:
To study the effect of FOXO1 deletion on the mineralization of cartilage,
paraffin imbedded sections from day 10 post fracture were stained with
Masson’s Trichrome, Alician blue, and Picrosirius Red. Quantification of the
stained sectioned will be carried on to study the differences between the
groups.
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Supplemental Figure 3: Fracture slides from day 10 stained with (A)
Masson’s Trichrom (B) Picrosirius Red (C) Alician blue.
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RNA sequencing:
RNA was isolated from fracture calluses from 8 different study groups.
NG WT and FOXO1 deleted, Diabetic WT and FOXO1 deleted on both day 10
and day 16 post fracture the RNA was sent for RNA-Seq using next
generation sequencing. In addition, RNA was isolated from both day 7 and day
13 from NG WT and FOXO1 deleted mice to look at the temporal effect of
FOXO1 deletion on cartilage maturation and degradation.
Furthermore, primary chondrocytes isolated from WT control or FOXO1
deleted mice were cultured and treated under different condition to study the
role of FOXO1 in chondrocytes proliferation, differentiation, apoptosis, and
angiogenesis under both normal condition and high glucose cultured media.
RNA was isolated from those cells and sent for RNA-Seq using next
generation sequencing.
Chondrocytes trans differentiation:
An in Vivo study is taking place to evaluate the chobdrocytes –
osteoblast trans differentiation and wither; 1- diabetes alter this process, 2FOXO1 mediate the trans differentiation process involved in the process.
Linage specific labeling was achieved using ROSA tomato reporter mouse
under the effect of Col2 promoter.
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FOXO1 activation under high glucose and AGE conditions:
To better understand how high glucose regulates FOXO1 activations.
ATDC5 murine chondrogenic were seeded and hypertrophic differentiation
was induced using DMEM/F12 media supplemented with 50µg/ml ascorbic
acid and 10mM β-glycerophosphate. Cells were incubated in high glucose
containing media with the use of the following; insulin, AKT inhibitor, TLR4
inhibitor, Sirt-1 inhibitor, HDAC inhibitor, N-Acetyl-L-cysteine, and L-NAME
hydrochloride. Another set of cells were incubated with AGE or unmodified
BSA control and were treated with the same inhibitors. To explore the effect of
insulin, phosphorylation, acetylation and ROS on FOXO1 activation under high
glucose conditions. Nuclear protein was extracted, western blot will be done.
The 96-well plates will be used for immunostaining with FOXO1 antibody
compared to matched IgG control. FOXO1 nuclear localization will be
quantified.
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